Skip to main content
Erschienen in: Metabolic Brain Disease 3/2016

21.01.2016 | Short Communication

Structural modeling of p.V31F variant in the aspartoacylase gene

verfasst von: Navaneethakrishnan Krishnamoorthy, Hatem Zayed

Erschienen in: Metabolic Brain Disease | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Aspartoacylase (ASPA) is an abundant enzyme in the brain, which catalyzes the conversion of N-acetylaspartate into acetate and aspartate, deficiency in its activity leads to degeneration of the white matter of the brain and is a recognized cause of Canavan disease (CD), which affect children. Although genotype-phenotype correlation have been reported for Canavan disease patients, this relationships is still not straightforward. In this communication, we use molecular modeling to address the structural consequences resulting from the missense variant p.V31F in the ASPA enzyme, which we previously reported in a homozygous form in an Egyptian patient with infantile CD. This modeling suggests that this variant brings significant changes to the catalytic core by introducing structural flexibility through neighbouring key residues. In particular, it provides a molecular explanation for the pathogenic effect of this variant and provides a meaningful genotype-phonotype relationships. The mutational impact appears to have an influence on the function of the protein and initiates molecular event for the mechanism of the disease.
Literatur
Zurück zum Zitat Baslow MH, Guilfoyle DN (2013) Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions. Biochimie 95:946–956CrossRefPubMed Baslow MH, Guilfoyle DN (2013) Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions. Biochimie 95:946–956CrossRefPubMed
Zurück zum Zitat Baslow MH, Resnik TR (1997) Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms. J Mol Neurosci 9:109–125CrossRefPubMed Baslow MH, Resnik TR (1997) Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms. J Mol Neurosci 9:109–125CrossRefPubMed
Zurück zum Zitat Bitto E, Bingman CA, Wesenberg GE, McCoy JG, Phillips GN Jr. (2007) Structure of aspartoacylase, the brain enzyme impaired in Canavan disease. Proc Natl Acad Sci U S A 104:456–461CrossRefPubMedPubMedCentral Bitto E, Bingman CA, Wesenberg GE, McCoy JG, Phillips GN Jr. (2007) Structure of aspartoacylase, the brain enzyme impaired in Canavan disease. Proc Natl Acad Sci U S A 104:456–461CrossRefPubMedPubMedCentral
Zurück zum Zitat Gajendrarao P, Krishnamoorthy N, Kassem H, Moharem-Elgamal S, Cecchi F, Olivotto I, Yacoub MH (2013) Molecular modeling of disease causing mutations in domain C1 of cMyBP-C. PLoS One 8:e59206CrossRefPubMedPubMedCentral Gajendrarao P, Krishnamoorthy N, Kassem H, Moharem-Elgamal S, Cecchi F, Olivotto I, Yacoub MH (2013) Molecular modeling of disease causing mutations in domain C1 of cMyBP-C. PLoS One 8:e59206CrossRefPubMedPubMedCentral
Zurück zum Zitat Hershfield JR, Pattabiraman N, Madhavarao CN, Namboodiri MA (2007) Mutational analysis of aspartoacylase: implications for Canavan disease. Brain Res 1148:1–14CrossRefPubMedPubMedCentral Hershfield JR, Pattabiraman N, Madhavarao CN, Namboodiri MA (2007) Mutational analysis of aspartoacylase: implications for Canavan disease. Brain Res 1148:1–14CrossRefPubMedPubMedCentral
Zurück zum Zitat Jakobs C, ten Brink HJ, Langelaar SA, Zee T, Stellaard F, Macek M, Srsnova K, Srsen S, Kleijer WJ (1991) Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, urine and amniotic fluid: accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease. J Inherit Metab Dis 14:653–660CrossRefPubMed Jakobs C, ten Brink HJ, Langelaar SA, Zee T, Stellaard F, Macek M, Srsnova K, Srsen S, Kleijer WJ (1991) Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, urine and amniotic fluid: accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease. J Inherit Metab Dis 14:653–660CrossRefPubMed
Zurück zum Zitat Kaul R, Casanova J, Johnson AB, Tang P, Matalon R (1991) Purification, characterization, and localization of aspartoacylase from bovine brain. J Neurochem 56:129–135CrossRefPubMed Kaul R, Casanova J, Johnson AB, Tang P, Matalon R (1991) Purification, characterization, and localization of aspartoacylase from bovine brain. J Neurochem 56:129–135CrossRefPubMed
Zurück zum Zitat Kaul R, Gao GP, Balamurugan K, Matalon R (1993) Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 5:118–123CrossRefPubMed Kaul R, Gao GP, Balamurugan K, Matalon R (1993) Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 5:118–123CrossRefPubMed
Zurück zum Zitat Le Coq J, Pavlovsky A, Malik R, Sanishvili R, Xu C, Viola RE (2008) Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue. Biochemistry 47:3484–3492CrossRefPubMedPubMedCentral Le Coq J, Pavlovsky A, Malik R, Sanishvili R, Xu C, Viola RE (2008) Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue. Biochemistry 47:3484–3492CrossRefPubMedPubMedCentral
Zurück zum Zitat Makarova KS, Grishin NV (1999) The Zn-peptidase superfamily: functional convergence after evolutionary divergence. J Mol Biol 292:11–17CrossRefPubMed Makarova KS, Grishin NV (1999) The Zn-peptidase superfamily: functional convergence after evolutionary divergence. J Mol Biol 292:11–17CrossRefPubMed
Zurück zum Zitat Matalon R, Michals-Matalon K (1993) Canavan disease. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K (eds) GeneReviews(R). University of Washington, Seattle. All rights reserved., Seattle (WA) Matalon R, Michals-Matalon K (1993) Canavan disease. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K (eds) GeneReviews(R). University of Washington, Seattle. All rights reserved., Seattle (WA)
Zurück zum Zitat Matalon R, Kaul R, Michals K (1993) Canavan disease: biochemical and molecular studies. J Inherit Metab Dis 16:744–752CrossRefPubMed Matalon R, Kaul R, Michals K (1993) Canavan disease: biochemical and molecular studies. J Inherit Metab Dis 16:744–752CrossRefPubMed
Zurück zum Zitat Matalon R, Michals K, Kaul R (1995) Canavan disease: from spongy degeneration to molecular analysis. J Pediatr 127:511–517CrossRefPubMed Matalon R, Michals K, Kaul R (1995) Canavan disease: from spongy degeneration to molecular analysis. J Pediatr 127:511–517CrossRefPubMed
Zurück zum Zitat Matalon R, Rady PL, Platt KA, Skinner HB, Quast MJ, Campbell GA, Matalon K, Ceci JD, Tyring SK, Nehls M, Surendran S, Wei J, Ezell EL, Szucs S (2000) Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med 2:165–175CrossRefPubMed Matalon R, Rady PL, Platt KA, Skinner HB, Quast MJ, Campbell GA, Matalon K, Ceci JD, Tyring SK, Nehls M, Surendran S, Wei J, Ezell EL, Szucs S (2000) Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med 2:165–175CrossRefPubMed
Zurück zum Zitat Moore RA, Le Coq J, Faehnle CR, Viola RE (2003) Purification and preliminary characterization of brain aspartoacylase. Arch Biochem Biophys 413:1–8CrossRefPubMed Moore RA, Le Coq J, Faehnle CR, Viola RE (2003) Purification and preliminary characterization of brain aspartoacylase. Arch Biochem Biophys 413:1–8CrossRefPubMed
Zurück zum Zitat Surendran S, Michals-Matalon K, Quast MJ, Tyring SK, Wei J, Ezell EL, Matalon R (2003) Canavan disease: a monogenic trait with complex genomic interaction. Mol Genet Metab 80:74–80CrossRefPubMed Surendran S, Michals-Matalon K, Quast MJ, Tyring SK, Wei J, Ezell EL, Matalon R (2003) Canavan disease: a monogenic trait with complex genomic interaction. Mol Genet Metab 80:74–80CrossRefPubMed
Zurück zum Zitat Zaki OK, El Abd HS, Mohamed SA, Zayed H (2015) Novel mutation in an Egyptian patient with infantile Canavan disease. Metab Brain Dis 30:1–5 Zaki OK, El Abd HS, Mohamed SA, Zayed H (2015) Novel mutation in an Egyptian patient with infantile Canavan disease. Metab Brain Dis 30:1–5
Zurück zum Zitat Zeng BJ, Wang ZH, Ribeiro LA, Leone P, De Gasperi R, Kim SJ, Raghavan S, Ong E, Pastores GM, Kolodny EH (2002) Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease. J Inherit Metab Dis 25:557–570CrossRefPubMed Zeng BJ, Wang ZH, Ribeiro LA, Leone P, De Gasperi R, Kim SJ, Raghavan S, Ong E, Pastores GM, Kolodny EH (2002) Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease. J Inherit Metab Dis 25:557–570CrossRefPubMed
Metadaten
Titel
Structural modeling of p.V31F variant in the aspartoacylase gene
verfasst von
Navaneethakrishnan Krishnamoorthy
Hatem Zayed
Publikationsdatum
21.01.2016
Verlag
Springer US
Erschienen in
Metabolic Brain Disease / Ausgabe 3/2016
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-016-9796-z

Weitere Artikel der Ausgabe 3/2016

Metabolic Brain Disease 3/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.